Uterine adenocarcinoma after GnRH agonist treatment.
We report endometrial adenocarcinoma in two patients shortly after suspending GnRH-agonist treatment for menometrorrhagia and uterine fibromata.
Dessole
S
S
Ruiu
G A
GA
Cherchi
P L
PL
Ambrosini
G
G
D000230:Adenocarcinoma / Q000139:chemically induced* / Q000175:diagnosis / Q000473:pathology; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007273:Injections, Intramuscular; D007889:Leiomyoma / Q000188:drug therapy* / Q000473:pathology; D016729:Leuprolide / Q000008:administration & dosage / Q000009:adverse effects*; D008796:Metrorrhagia / Q000188:drug therapy* / Q000473:pathology; D008875:Middle Aged; D009215:Myometrium / Q000473:pathology; D016609:Neoplasms, Second Primary / Q000139:chemically induced* / Q000175:diagnosis / Q000473:pathology; D017329:Triptorelin Pamoate / Q000008:administration & dosage / Q000009:adverse effects*; D014594:Uterine Neoplasms / Q000139:chemically induced* / Q000188:drug therapy* / Q000473:pathology
D018931:Antineoplastic Agents, Hormonal; D017329:Triptorelin Pamoate; D016729:Leuprolide